EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tannic acid, an IL-1β-direct binding compound, ameliorates IL-1β-induced inflammation and cartilage degradation by hindering IL-1β-IL-1R1 interaction

Hae-Ri Lee, Young-Jin Jeong, Joong-Woon Lee, JooYeon Jhun, Hyun Sik Na, Keun-Hyung Cho, Seok Jung Kim, Mi-La Cho, Tae-Hwe Heo iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Hae-Ri Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma L…. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Osteoarthritis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology, Research Fund, 2023 of The Catholic University of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-1β (IL-1β) is one of the most potent pro-inflammatory cytokines implicated in a wide range of autoinflammatory, autoimmune, infectious, and degenerative diseases. Therefore, many researchers have focused on developing therapeutic molecules that inhibit IL-1β-IL-1 receptor 1 (IL-1R1) interaction for the treatment of IL-1-related diseases. Among IL-1-related diseases, osteoarthritis (OA), is characterized by progressive cartilage destruction, chondrocyte inflammation, and extracellular matrix (ECM) degradation. Tannic acid (TA) has been proposed to have multiple beneficial effects, including anti-inflammatory, anti-oxidant, and anti-tumor activities. However, it is unclear whether TA plays a role in anti-IL-1β activity by blocking IL-1β-IL-1R1 interaction in OA. In this study, we report the anti-IL-1β activity of TA in the progression of OA in both in vitro human OA chondrocytes and in vivo rat OA models. Herein, using-ELISA-based screening, natural compound candidates capable of inhibiting the IL-1β-IL-1R1 interaction were identified. Among selected candidates, TA showed hindering IL-1β-IL-1R1 interaction by direct binding to IL-1β using surface plasmon resonance (SPR) assay. In addition, TA inhibited IL-1β bioactivity in HEK-Blue IL-1-dependent reporter cell line. TA also inhibited IL-1β-induced expression of inducible nitric oxide synthase (NOS2), cyclooxygenase-2 (COX-2), IL-6, tumor necrosis factor-alpha (TNF-α), nitric oxide (NO), and prostaglandin E2 (PGE2) in human OA chondrocytes. Moreover, TA downregulated IL-1β-stimulated matrix metalloproteinase (MMP)3, MMP13, ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)4, and ADAMTS5, while upregulating collagen type II (COL2A1) and aggrecan (ACAN). Mechanistically, we confirmed that TA suppressed IL-1β-induced MAPK and NF-κB activation. The protective effects of TA were also observed in a monosodium iodoacetamide (MIA)-induced rat OA model by reducing pain and cartilage degradation and inhibiting IL-1β-mediated inflammation. Collectively, our results provide evidence that TA plays a potential role in OA and IL-1β-related diseases by hindering IL-1β-IL-1R1 interaction and suppressing IL-1β bioactivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory AgentsOsteoarthritisRatsHumansAnimalsInterleukin-1betaNF-kappa BInflammationCartilageChondrocytesTanninsCells, Cultured

Substanzen

Interleukin-1betaAnti-Inflammatory AgentsNF-kappa BTannins

Autor:innen und Institutionen

  • Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Seoul,…
  • The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Lab of Translational Immuno Medicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Orthopedic Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Tae-Hwe Heo

Förderung

  • the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology
  • Research Fund, 2023 of The Catholic University of Korea

Zitieren

APA

Lee, H. R., Jeong, Y. J., Lee, J. W., Jhun, J., Na, H. S., Cho, K. H., Kim, S. J., Cho, M. L., & Heo, T. H. (2023). Tannic acid, an IL-1β-direct binding compound, ameliorates IL-1β-induced inflammation and cartilage degradation by hindering IL-1β-IL-1R1 interaction. PLOS ONE. https://doi.org/10.1371/journal.pone.0281834

Vancouver

Lee HR, Jeong YJ, Lee JW, Jhun J, Na HS, Cho KH, et al. Tannic acid, an IL-1β-direct binding compound, ameliorates IL-1β-induced inflammation and cartilage degradation by hindering IL-1β-IL-1R1 interaction. PLOS ONE. 2023. doi:10.1371/journal.pone.0281834

BibTeX
@article{Lee2023,
  author = {Lee, Hae-Ri and Jeong, Young-Jin and Lee, Joong-Woon and Jhun, JooYeon and Na, Hyun Sik and Cho, Keun-Hyung and Kim, Seok Jung and Cho, Mi-La and Heo, Tae-Hwe},
  title = {Tannic acid, an IL-1β-direct binding compound, ameliorates IL-1β-induced inflammation and cartilage degradation by hindering IL-1β-IL-1R1 interaction},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281834}
}
Kostenlos starten →